News

The policy statement was informed by an FTC workshop held last year to examine how such drugs are marketed to consumers. The FTC also released its staff report

The financing from a single family office that is an existing investor includes the sale of a $1 million convertible note and up to $10 million in future equity

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for Phase II for ulcerative colitis, diseases that sit

Sirukumab is being co-developed by Janssen Biologics (Ireland) and GSK. The companies unveiled results from two pivotal phase 3 studies assessing subcutaneous (SC) sirukumab, a human anti-interleukin (IL)-6

APX001 has received orphan drug designation for four distinct indications: the treatment of invasive candidiasis, invasive aspergillosis, coccidioidomycosis, and rare mold infections caused by Scedosporium spp., Fusarium spp.,

har Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained

Virttu, based in Glasgow, Scotland, is a privately-held biopharmaceutical company focused on the development of oncolytic virus therapy for treatment of cancer. Virttu's lead product candidate Seprehvir (HSV1716) is

Ezutromid dosing is expected to follow within a screening period of up to 28 days.  Enrolment and dosing of patients into PhaseOut DMD in the UK is ongoing.

In the global phase 3, multicenter, randomized 24-week, double-blind, placebo-controlled Strive study, 955 patients were randomized to receive once-monthly subcutaneous placebo or erenumab (70 mg or 140 mg)